102.62 USD
-3.59 (-3.38%)
103.01 USD
+0.39 (+0.38%)
Overall INCY gets a fundamental rating of 6 out of 10. We evaluated INCY against 525 industry peers in the Biotechnology industry. INCY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. INCY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make INCY a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
- INCY had positive earnings in the past year.
- INCY had a positive operating cash flow in the past year.
- Of the past 5 years INCY 4 years were profitable.
- Of the past 5 years INCY 4 years had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 18.78%, INCY belongs to the top of the industry, outperforming 96.76% of the companies in the same industry.
- INCY's Return On Equity of 25.55% is amongst the best of the industry. INCY outperforms 96.95% of its industry peers.
- INCY's Return On Invested Capital of 19.88% is amongst the best of the industry. INCY outperforms 97.71% of its industry peers.
- INCY had an Average Return On Invested Capital over the past 3 years of 7.24%. This is significantly below the industry average of 18.07%.
- The 3 year average ROIC (7.24%) for INCY is below the current ROIC(19.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROIC | 19.88% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
1.3 Margins
- INCY has a better Profit Margin (24.69%) than 94.86% of its industry peers.
- In the last couple of years the Profit Margin of INCY has declined.
- The Operating Margin of INCY (26.10%) is better than 96.00% of its industry peers.
- In the last couple of years the Operating Margin of INCY has declined.
- With an excellent Gross Margin value of 93.47%, INCY belongs to the best of the industry, outperforming 94.48% of the companies in the same industry.
- INCY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% |
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
2. Health
2.1 Basic Checks
- INCY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for INCY has been reduced compared to 1 year ago.
- The number of shares outstanding for INCY has been reduced compared to 5 years ago.
- INCY has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 9.40 indicates that INCY is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 9.40, INCY belongs to the best of the industry, outperforming 82.29% of the companies in the same industry.
- The Debt to FCF ratio of INCY is 0.03, which is an excellent value as it means it would take INCY, only 0.03 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of INCY (0.03) is better than 96.38% of its industry peers.
- A Debt/Equity ratio of 0.01 indicates that INCY is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.01, INCY is in line with its industry, outperforming 45.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 9.4 |
ROIC/WACC2.24
WACC8.87%
2.3 Liquidity
- A Current Ratio of 3.20 indicates that INCY has no problem at all paying its short term obligations.
- INCY's Current ratio of 3.20 is on the low side compared to the rest of the industry. INCY is outperformed by 61.90% of its industry peers.
- A Quick Ratio of 3.13 indicates that INCY has no problem at all paying its short term obligations.
- INCY has a Quick ratio of 3.13. This is in the lower half of the industry: INCY underperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 |
3. Growth
3.1 Past
- INCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 575.79%, which is quite impressive.
- Measured over the past years, INCY shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.21% on average per year.
- Looking at the last year, INCY shows a quite strong growth in Revenue. The Revenue has grown by 18.09% in the last year.
- Measured over the past years, INCY shows a quite strong growth in Revenue. The Revenue has been growing by 14.46% on average per year.
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
3.2 Future
- The Earnings Per Share is expected to grow by 29.11% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 1.31% on average over the next years.
EPS Next Y428.71%
EPS Next 2Y146.91%
EPS Next 3Y91%
EPS Next 5Y29.11%
Revenue Next Year18.23%
Revenue Next 2Y14.6%
Revenue Next 3Y12.92%
Revenue Next 5Y1.31%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 15.98, INCY is valued correctly.
- INCY's Price/Earnings ratio is rather cheap when compared to the industry. INCY is cheaper than 95.43% of the companies in the same industry.
- When comparing the Price/Earnings ratio of INCY to the average of the S&P500 Index (26.94), we can say INCY is valued slightly cheaper.
- INCY is valuated correctly with a Price/Forward Earnings ratio of 12.75.
- Based on the Price/Forward Earnings ratio, INCY is valued cheaper than 96.76% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.94, INCY is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.98 | ||
| Fwd PE | 12.75 |
4.2 Price Multiples
- 95.43% of the companies in the same industry are more expensive than INCY, based on the Enterprise Value to EBITDA ratio.
- 96.00% of the companies in the same industry are more expensive than INCY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.83 | ||
| EV/EBITDA | 12.97 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- INCY has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as INCY's earnings are expected to grow with 91.00% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y146.91%
EPS Next 3Y91%
5. Dividend
5.1 Amount
- No dividends for INCY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
102.62
-3.59 (-3.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28 2025-10-28/bmo
Earnings (Next)02-09 2026-02-09/amc
Inst Owners105.27%
Inst Owner Change0.3%
Ins Owners0.96%
Ins Owner Change-11.29%
Market Cap20.15B
Revenue(TTM)4.81B
Net Income(TTM)1.19B
Analysts75.63
Price Target104.13 (1.47%)
Short Float %5.48%
Short Ratio4.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.23%
Min EPS beat(2)4.72%
Max EPS beat(2)33.74%
EPS beat(4)3
Avg EPS beat(4)10.09%
Min EPS beat(4)-10.01%
Max EPS beat(4)33.74%
EPS beat(8)3
Avg EPS beat(8)-1.54%
EPS beat(12)6
Avg EPS beat(12)-3.05%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)2
Avg Revenue beat(2)5.08%
Min Revenue beat(2)3.45%
Max Revenue beat(2)6.72%
Revenue beat(4)4
Avg Revenue beat(4)3.8%
Min Revenue beat(4)1.09%
Max Revenue beat(4)6.72%
Revenue beat(8)5
Avg Revenue beat(8)1.4%
Revenue beat(12)7
Avg Revenue beat(12)0.24%
Revenue beat(16)9
Avg Revenue beat(16)0.48%
PT rev (1m)8.17%
PT rev (3m)21.22%
EPS NQ rev (1m)0.18%
EPS NQ rev (3m)7.13%
EPS NY rev (1m)0%
EPS NY rev (3m)10.61%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)2.46%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)2.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.98 | ||
| Fwd PE | 12.75 | ||
| P/S | 4.19 | ||
| P/FCF | 16.83 | ||
| P/OCF | 16.1 | ||
| P/B | 4.33 | ||
| P/tB | 4.6 | ||
| EV/EBITDA | 12.97 |
EPS(TTM)6.42
EY6.26%
EPS(NY)8.05
Fwd EY7.84%
FCF(TTM)6.1
FCFY5.94%
OCF(TTM)6.37
OCFY6.21%
SpS24.52
BVpS23.69
TBVpS22.29
PEG (NY)0.04
PEG (5Y)N/A
Graham Number58.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROCE | 25.17% | ||
| ROIC | 19.88% | ||
| ROICexc | 48.14% | ||
| ROICexgc | 55.55% | ||
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% | ||
| FCFM | 24.87% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexgc growth 3Y-34.92%
ROICexgc growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 59.08% | ||
| Cap/Sales | 1.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.81% | ||
| Profit Quality | 100.71% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z | 9.4 |
F-Score7
WACC8.87%
ROIC/WACC2.24
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
EPS Next Y428.71%
EPS Next 2Y146.91%
EPS Next 3Y91%
EPS Next 5Y29.11%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
Revenue Next Year18.23%
Revenue Next 2Y14.6%
Revenue Next 3Y12.92%
Revenue Next 5Y1.31%
EBIT growth 1Y6374.01%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year366.76%
EBIT Next 3Y85.61%
EBIT Next 5Y26.81%
FCF growth 1Y106.03%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y97.88%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%
INCYTE CORP / INCY FAQ
What is the fundamental rating for INCY stock?
ChartMill assigns a fundamental rating of 6 / 10 to INCY.
What is the valuation status of INCYTE CORP (INCY) stock?
ChartMill assigns a valuation rating of 8 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.
How profitable is INCYTE CORP (INCY) stock?
INCYTE CORP (INCY) has a profitability rating of 7 / 10.
How financially healthy is INCYTE CORP?
The financial health rating of INCYTE CORP (INCY) is 7 / 10.
Can you provide the expected EPS growth for INCY stock?
The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 428.71% in the next year.